Xu Huimin, He Yanan, Xu Lingcheng, Yan Xiaofeng, Dai Haibin
Int J Clin Pharmacol Ther. 2015 Jun;53(6):430-7. doi: 10.5414/CP202243.
To examine prescription trends and patterns in five antihypertensive drug classes during 2007 - 2012 in China.
A retrospective time series data was investigated from 2007 to 2012. Prescription data of five classes of antihypertensive drugs (calcium channel blockers (CCBs), angiotensin receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs), β-blockers, and diuretics) were accessed from the Hospital Prescription Analysis Program Database, including 59 hospitals in four cities in China. The drugs were coded using the Anatomic Chemical Therapeutic (ATC) classification. Quantities were standardized using the defined daily dose (DDD) measurement methodology.
The total number of DDDs of the five classes of antihypertensive drugs prescribed in the sample hospitals increased by 83.3% and the total cost of antihypertensive drugs increased by 92.4% from 2007 to 2012. During the whole study period, CCBs, ARBs, ACEIs, β-blockers, and diuretics represented in DDDs 42.8%, 28.3%, 13.3%, 10.8%, and 4.8%, respectively, of the total five classes of anti-hypertensive drugs. The average annual increase rate of ARBs, β-blockers, CCBs, ACEIs, and diuretics, in DDDs, was 23.4%, 13.3%, 13.2%, 1.4%, and -4.2%, respectively
The consumption of the five classes of antihypertensive drugs in China nearly doubled from 2007 to 2012. The top-prescribed antihypertensive drug classes were CCBs and ARBs, and the latter increased most rapidly.
研究2007年至2012年中国五类抗高血压药物的处方趋势和模式。
对2007年至2012年的回顾性时间序列数据进行调查。从医院处方分析程序数据库获取五类抗高血压药物（钙通道阻滞剂（CCB）、血管紧张素受体阻滞剂（ARB）、血管紧张素转换酶抑制剂（ACEI）、β受体阻滞剂和利尿剂）的处方数据，该数据库涵盖中国四个城市的59家医院。药物使用解剖学化学治疗（ATC）分类进行编码。使用限定日剂量（DDD）测量方法对数量进行标准化。
2007年至2012年，样本医院开具的五类抗高血压药物的总限定日剂量增加了83.3%，抗高血压药物的总成本增加了92.4%。在整个研究期间，CCB、ARB、ACEI、β受体阻滞剂和利尿剂在五类抗高血压药物中的限定日剂量分别占42.8%、28.3%、13.3%、10.8%和4.8%。ARB、β受体阻滞剂、CCB、ACEI和利尿剂的限定日剂量平均年增长率分别为23.4%、13.3%、13.2%、1.4%和-4.2%。
2007年至2012年，中国五类抗高血压药物的消费量几乎翻了一番。处方量最大的抗高血压药物类别是CCB和ARB，后者增长最为迅速。
